Claims for Patent: 7,666,839

Summary for Patent: 7,666,839

Title:	Methods of treatment using specific binding agents of human angiopoietin-2
Abstract:	Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
Inventor(s):	Oliner; Jonathan Daniel (Newbury Park, CA), Min; Hosung (Newbury Park, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	11/499,891
Patent Claims:	1. A method for treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a peptide or peptibody capable of binding Ang-2, wherein said peptide or peptibody comprises an amino acid sequence of the formula: TABLE-US-00057 Cg.sup.2Gg.sup.4g.sup.5DPFTg.sup.10GCg.sup.13 (SEQ ID NO: 75) wherein g.sup.2 is an acidic amino acid residue; g.sup.4 is a neutral hydrophobic amino acid residue; g.sup.5 is E, D, or Q; g.sup.10 is a neutral hydrophobic or neutral polar amino acid residue; g.sup.13 is an acidic residue; and physiologically acceptable salts thereof. 2. The method according to claim 1 wherein the peptide or peptibody comprises an amino acid sequence of the formula: TABLE-US-00058 (SEQ ID NO: 158) h.sup.1h.sup.2h.sup.3h.sup.4Ch.sup.6Gh.sup.8h.sup.9DPFTh.sup.14GCh.sup.17- h.sup.18h.sup.19h.sup.20 wherein, h.sup.1 is absent or a neutral hydrophobic, neutral polar, or a basic amino acid residue; h.sup.2 is a neutral hydrophobic or neutral polar amino acid residue; h.sup.3 is an acidic amino acid residue; h.sup.4 is a neutral hydrophobic or neutral polar amino acid residue; h.sup.6 is an acidic amino acid residue; h.sup.8 is a neutral hydrophobic amino acid residue; h.sup.9 is E, D, or Q; h.sup.14 is a neutral hydrophobic or neutral polar amino acid residue; h.sup.17 is an acidic amino acid residue; h.sup.18 is a neutral hydrophobic, neutral polar, or a basic amino acid residue; h.sup.19 is a neutral hydrophobic or neutral polar amino acid residue; and h.sup.20 is absent or an amino acid residue; and physiologically acceptable salts thereof. 3. The method according to claim 2 wherein: h.sup.1 is absent, or A, L, M, G, K, or H; h.sup.2 is L, F, or Q; h.sup.3 is D or E; h.sup.4 is W or Y; h.sup.6 is D or E; h.sup.8 is V or M; h.sup.14 is F or Q; h.sup.17 is D or E; h.sup.18 is M, Y, N, or K; h.sup.19 is L or Q; and h.sup.20 is absent or M, T, G, S, D, K, or R; and physiologically acceptable salts thereof. 4. The method according to claim 2 wherein the peptide or peptibody comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 5, and SEQ ID NO: 149 to SEQ ID NO: 157, inclusive, and physiologically acceptable salts thereof. 5. The method according to claims 1 or claim 2 further comprising administering at least one anti-inflammatory agent. 6. The method according to claim 5 wherein the anti-inflammatory agent comprises at least one of a disease modifying anti-rheumatic drug (DMARD), slow acting anti-rheumatic drug (SAARD), and non-steroidal anti-rheumatic drug (NSAID). 7. The method according to claim 5 wherein the anti-inflammatory agent comprises at least one of methotrexate, a TNF inhibitor, a IL-1 inhibitor, a TACE inhibitor, a COX-2 inhibitor, and a P-38 inhibitor. 8. The method according to claim 7 wherein the TNF inhibitor comprises at least one of etanercept, adalimumab, pegsunercept sTNF-R1, onercept, and infliximab. 9. The method according to claim 7 wherein said IL-1 inhibitor is at least one of anakinra, IL-1 TRAP, IL-1 antibody, and soluble IL-1 receptor. 10. The method according to claim 5 wherein the administration is concurrent administration. 11. The method according to claim 5 wherein the administration is non-concurrent administration. 12. The method according to claim 2, further comprising administering at least one anti-inflammatory agent. 13. The method according to claim 3, further comprising administering at least one anti-inflammatory agent.

Details for Patent 7,666,839

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2021-10-11
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2021-10-11
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2021-10-11
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2021-10-11